Barclays PLC Grows Stock Holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO)

Barclays PLC lifted its position in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 243.6% in the 3rd quarter, Holdings Channel.com reports. The firm owned 59,502 shares of the company’s stock after purchasing an additional 42,185 shares during the period. Barclays PLC’s holdings in ALX Oncology were worth $107,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the company. XTX Topco Ltd purchased a new stake in shares of ALX Oncology during the 3rd quarter worth $578,000. Wellington Management Group LLP lifted its position in shares of ALX Oncology by 15.2% during the 3rd quarter. Wellington Management Group LLP now owns 167,831 shares of the company’s stock worth $305,000 after purchasing an additional 22,114 shares during the last quarter. Verition Fund Management LLC lifted its position in shares of ALX Oncology by 308.4% during the 3rd quarter. Verition Fund Management LLC now owns 133,025 shares of the company’s stock worth $242,000 after purchasing an additional 100,454 shares during the last quarter. Walleye Capital LLC lifted its position in shares of ALX Oncology by 110.3% during the 3rd quarter. Walleye Capital LLC now owns 230,875 shares of the company’s stock worth $420,000 after purchasing an additional 121,113 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of ALX Oncology by 207.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 83,042 shares of the company’s stock worth $151,000 after purchasing an additional 56,028 shares during the last quarter. 97.97% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other ALX Oncology news, Director Rekha Hemrajani bought 30,000 shares of ALX Oncology stock in a transaction dated Monday, December 2nd. The stock was acquired at an average cost of $1.55 per share, with a total value of $46,500.00. Following the completion of the acquisition, the director now owns 33,000 shares of the company’s stock, valued at approximately $51,150. This represents a 1,000.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last three months, insiders sold 14,443 shares of company stock valued at $23,309. Insiders own 33.40% of the company’s stock.

ALX Oncology Price Performance

Shares of ALXO opened at $1.63 on Friday. The firm has a fifty day moving average price of $1.61 and a 200 day moving average price of $2.43. ALX Oncology Holdings Inc. has a 1-year low of $1.19 and a 1-year high of $17.83. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82. The stock has a market cap of $85.97 million, a PE ratio of -0.55 and a beta of 0.98.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on ALXO shares. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a research report on Wednesday, December 18th. Jefferies Financial Group cut shares of ALX Oncology from a “buy” rating to a “hold” rating and reduced their price target for the company from $12.00 to $2.00 in a research report on Thursday, December 19th. Finally, HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of ALX Oncology in a research report on Wednesday, December 18th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $8.50.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.